Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Abemaciclib with Rifampin in Healthy Subjects
NCT02256267Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration (Cmax) of LY2835219 and Area Under the Concentration Time Curve AUC(0-∞) of LY2835219. Started Oct 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02256267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256267.